| 1:30 PM - 4:30 PM |
Pre-Course: Advancing Innovation, Collaboration, and Clinical Excellence in Advanced Cancer Care
The session will highlight the roles of advanced practice providers in the specialty of Surgical Oncology, enhance clinical knowledge of advanced cancer therapies, and provide structured opportunities for interprofessional networking. Attendees will gain a comprehensive Understanding of how APPs contribute to the multidisciplinary care team, utilizing their clinical expertise and knowledge of advanced cancers to enhance outcomes in patient care.
Key highlights of the Advanced Practice Providers Pre-Course 2025 include:
- In-depth presentations on the diverse responsibilities and contributions of APPs in the management of complex cancers
- Expert-led interdisciplinary sessions showcasing the latest advancements in cancer management and innovative treatment modalities
- Interactive case studies designed to deepen clinical expertise and emphasize the role of APPs in the delivery of quality advanced cancer care
- Insightful discussion exploring the evolving scope of practice and emerging opportunities for APPs in this field of practice
- Panel discussions that facilitate the exchange of ideas, the sharing of best practices, and collaborative problem-solving among providers
- Structured networking opportunities to promote the building of collaborative relationships that support ongoing learning, professional development, and scholarship
Join us for this enriching pre-course to advance your clinical practice, stay abreast of the latest innovations in advanced cancer therapies, and connect with fellow advanced practice professional in Surgical Oncology dedicated to excellence in cancer care.
Upon completion of this session, participants should gain strategies to:
- Identify the roles of the advanced practice provider in the delivery of comprehensive cancer care in the clinical specialty of Surgical Oncology.
- Describe the current evidence-based therapies associated with the management of advanced cancer.
- Discuss opportunities to facilitate ongoing professional development and promote interdisciplinary collaboration in clinical practice and research.
| 1:30 - 2:00 p.m. |
Keynote Presentation
Michael E. Lidsky, MD
|
| 2:00 - 2:30 p.m. |
Interdisciplinary Collaboration in the Surgical Management of Peritoneal Surface Malignancies
Heritage 3/4/5 |
|
Saturday, February 15
|
| 7:00 AM - 7:30 AM |
Breakfast
|
Heritage 1/2/Hall |
| 7:00 AM - 3:00 PM |
Exhibits
|
Heritage 1/2/Hall |
| 7:00 AM - 3:30 PM |
Registration
|
The Canal Club Foyer |
| 7:15 AM - 7:30 AM |
Opening Remarks
|
Orangedale Ballroom |
| 7:30 AM - 9:00 AM |
Abstract Presentations: PSM Clinical Outcomes
7:30-7:37 a.m.
1. Productivity Analysis of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Operative Procedures: Implications for Surgeons and Practice Planning
Erin A. Strong, MD, MBA, MPH
7:37-7:39 a.m.
Discussion Q&A
7:39-7:46 a.m.
2. Development of Peritoneal Complications in Patients with Peritoneal Metastases Who are Not Candidates for Cytoreductive Surgery
Beatrice J. Sun, MD
7:46-7:48 a.m.
Discussion Q&A
7:48-7:55 a.m.
3. Anastomotic Leaks and the Role of Diverting Stomas in Low Anterior Resection with HIPEC
Apeksha Dave
7:55-7:57 a.m.
Discussion Q&A
7:57-8:04 a.m.
4. Leveraging Machine Learning to Predict Completeness of Cytoreduction after CRS-HIPEC
Amir Ashraf Ganjouei
8:04-8:06 a.m.
Discussion Q&A
8:06-8:13 a.m.
5. A Cost Analysis of Acute Pain Management after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
Noah Brown, MD
8:13-8:15 a.m.
Discussion Q&A
8:15-8:22 a.m.
6. Perioperative and oncologic outcomes following combined peritoneal and liver resection/ablation for metastatic colorectal cancer
Ahmed Hamed, MD, MS
8:22-8:24 a.m.
Discussion Q&A
8:24-8:31 a.m.
7. Decision Regret and Quality of Life in Caregivers of Patients with Appendiceal Cancer Undergoing Hyperthermic Intraperitoneal Chemotherapy
Alissa Greenbaum, MD
8:31-8:33 a.m.
Discussion Q&A
8:33-8:40 a.m.
8. Validation of Nomograms Predicting Survival in Patients undergoing CRS-HIPEC for Peritoneal Dissemination of Appendiceal Cancer
Nicole Y. Xu, BA
8:40-8:42 a.m.
Discussion Q&A
8:42-8:49 a.m.
9. Racial and Geographic Disparities in Utilization of CRS-HIPEC for Metastatic Mucinous Appendiceal Tumors: A National Analysis
Salvador Rodriguez Franco, MD
8:49-8:51 a.m.
Discussion Q&A
8:51-8:58 a.m.
10. Tailored Surveillance for Mucinous Appendix Cancer after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Vladislav Kovalik, MD, MSPH
8:58-9:00 a.m.
Discussion Q&A
|
Orangedale Ballroom |
| 9:00 AM - 10:00 AM |
Symposium: Multimodal Management of Unresectable Colorectal Liver Metastases
Presentations covering modern multimodal management options for patients with initially unresectable colorectal liver metastases
Upon completion of this session, participants should gain strategies to:
- Plan sequencing of treatment options to include regional and locally ablative therapies such as HAI, IRE, and SBRT.
- Understand the emerging data for histotripsy as treatment for liver metastases.
- Understand the current and evolving indications and criteria for liver transplant for patients with unresectable liver metastases.
| 9:00 - 9:12 a.m. |
IRE for Unresectable Colorectal Liver Metastases
Kevin C. Soares, MD
|
| 9:12 - 9:24 a.m. |
HAI for Unresectable Colorectal Liver Metastases
Chandrashekar Padmanabhan, MD
|
| 9:24 - 9:36 a.m. |
Histotripsy and SBRT for Unresectable Colorectal Liver Metastases
Clifford S. Cho, MD
|
| 9:36 - 9:48 a.m. |
Liver Transplant for Unresectable Colorectal Liver Metastases
Eve Simoneau, MD, PhD
|
| 9:48 - 10:00 a.m. |
Discussion Q&A
Panel |
|
Orangedale Ballroom |
| 10:00 AM - 10:30 AM |
Networking Refreshment Break
|
Heritage 1/2/Hall |
| 10:30 AM - 12:00 PM |
Chair Assembly
10:30 - 10:45 a.m.
Chair Lecture
Maheswari Senthil, MD
10:45 - 11:30 a.m.
Surgeon Scientists in the US: A Bright Future
Martha A. Zeiger, MD, FACS
11:30 a.m. - 12:00 p.m.
Keynote TalkBack
|
Orangedale Ballroom |
| 12:00 PM - 1:00 PM |
Industry Spotlight Presentations
12:10 - 12:25 p.m.
Industry Spotlight Session 1 (Non-CME)
Company
12:30 - 12:45 p.m.
Industry Spotlight Session 2 (Non-CME)
Company
|
Heritage 1/2/Hall |
| 12:00 PM - 1:00 PM |
Lunch Break
|
Heritage 1/2/Hall |
| 1:00 PM - 2:00 PM |
Abstract Presentations: HPB
1:02-1:09 p.m.
11. ctDNA as a novel biomarker of treatment efficacy in patients with unresectable colorectal liver metastases treated with hepatic arterial infusion
Annie Liu, MD, PhD
1:09-1:11 p.m.
Discussion Q&A
1:11-1:18 p.m.
12. Surgical stress promotes development of colorectal liver metastases via modulation of hepatic regulatory T cells
Grace Wu, MD
1:18-1:20 p.m.
Discussion Q&A
1:20-1:27 p.m.
13. Reduced hepatotoxicity and equivalent survival with a lower hepatic arterial floxuridine starting dose in the adjuvant treatment of colorectal cancer liver metastases
Kevin P. Labadie
1:27-1:29 p.m.
Discussion Q&A
1:29-1:36 p.m.
14. Perceived Challenges and Strategies in Managing Biliary Sclerosis: A Qualitative Study of Hepatic Arterial Infusion Pump Chemotherapy Providers
Lauren M. Janczewski, MD, MS
1:36-1:38 p.m.
Discussion Q&A
1:38-1:45 p.m.
15. Perioperative Outcomes and Technical Feasibility of A Phase II Trial of Hepatic Artery Infusional Floxuridine with Systemic Chemotherapy in Treatment of Pancreatic Cancer Liver Metastases
Jason M. Aubrey, MD
1:45-1:47 p.m.
Discussion Q&A
1:47-1:54 p.m.
16. Histotripsy for the Treatment of Liver Tumors: A review of patients treated at a single institution
Evan S. Ong, MD, MS
1:54-1:56 p.m.
Discussion Q&A
|
Orangedale Ballroom |
| 2:05 PM - 3:35 PM |
Workshop: Management of Hepatic Artery Infusion Pump Therapy-Related Complications (Non-CME)
This session will be a case-based discussion of commonly and uncommonly encountered complications related to HAI pump therapy with providing expert opinion and experience on diagnosis, workup, and management of these difficult scenarios. Session will conclude with a panel discussion.
Upon completion of this session, participants should gain strategies to:
- Understand the diagnosis, workup, and management of HAI pump pocket complications
- Understand the diagnosis, workup, troubleshooting, and management of device or catheter-related complications
- Understand the diagnosis, workup, and management of arterial or perfusion-related complications/issues related to HAI therapy
- Understand the diagnosis, workup, and management of FUDR- or systemic therapy-related toxicity, including biliary sclerosis and hepatotoxicity
| 2:05 - 2:20 p.m. |
HAI Pump Pocket Complications and Management
Patrick Varley, MD
|
| 2:20 - 2:35 p.m. |
Device and Catheter-Related Complications and Troubleshooting
Laleh Melstrom, MD
|
| 2:35 - 2:50 p.m. |
Diagnosis and Management of Arterial Complications and Perfusion Problems
Michael Cavnar, MD
|
| 2:50 - 3:05 p.m. |
Biliary Sclerosis and Hepatotoxicity: Pump and Systemic Considerations
J. Eva Selfridge
|
| 3:05 - 3:35 p.m. |
Panel discussion & cases – “I wish I knew this before starting a pump program…”
Panel
|
|
Orangedale Ballroom |
| 2:05 PM - 3:35 PM |
Workshop: Palliative Surgery in Advanced Cancer (Non-CME)
This session will focus on the treatment of patients with advanced stage cancer that are not candidates for curative-intent therapy. Specific topics covered will be: goals of therapy other than cure and how to discuss these with patients, systemic therapy options for patients with incurable disease, and when surgery is appropriate in the palliative setting.
Upon completion of this session, participants should gain strategies to:
- Compassionately communicate and establish clear and realistic goals of care with patients who have incurable disease
- Explore systemic therapy options for patients with incurable disease, including standard therapies, targeted therapies, and clinical trials
- Understand when surgery may be appropriate in the palliative setting, both for symptom control and for disease control
| 2:05 - 2:07 p.m. |
Introduction
Jula Veerapong, MD; Kaitlyn J. Kelly, MD, MS
|
| 2:07 - 2:27 p.m. |
Palliative Care: Goals of Care Discussions and Timing
Elizabeth Lilley, MD, MPH
|
| 2:27 - 2:47 p.m. |
Surgical Palliation Options
Bridget Fahy, MD
|
| 2:47 - 3:07 p.m. |
Navigating Systemic Therapy Options
Robert Krouse, MD, MS
|
| 3:07 - 3:35 p.m. |
Case Reviews & Panel Discussion
Panel
|
|
Heritage 3/4/5 |
|
Sunday, February 16
|
| 7:00 AM - 7:30 AM |
Breakfast
|
Heritage 1/2/Hall |
| 7:00 AM - 4:00 PM |
Exhibits
|
Heritage 1/2/Hall |
| 7:00 AM - 5:00 PM |
Registration
|
The Canal Club Foyer |
| 7:30 AM - 9:00 AM |
Abstract Presentations: PSM Appendix and CRC Translational Science
7:30-7:37 a.m.
17. Discovery of Drug Response-Associated Mutations in Mucinous Metastatic Appendiceal Cancer Using a Patient-Derived Tumor Organoid Platform
Daniel J. Gironda, BA
7:37-7:39 a.m.
Discussion Q&A
7:39-7:46 a.m.
18. Next generation sequencing identifies key targetable mutations in the treatment of appendiceal neoplasms
Rui Zheng-Pywell
7:46-7:48 a.m.
Discussion Q&A
7:48-7:55 a.m.
19. Tissue-based biomarkers of response to immune checkpoint blockade (ICB) in metastatic appendiceal adenocarcinoma (AA): Validating spatial transcriptomics and proteomics of trial participants’ surgical specimens.
Eleanor A. Fallon, MD
7:55-7:57 a.m.
Discussion Q&A
7:57-8:04 a.m.
20. Novel patient-derived tumor slice culture for appendiceal and colorectal peritoneal metastases
Jack Cernak
8:04-8:06 a.m.
Discussion Q&A
8:06-8:13 a.m.
21. Fusobacterium nucleatum Tissue Density is Associated with Patient, Tumor, and Immune Microenvironment Features and Overall Survival in Appendix Cancer
Christopher Sherry, DO
8:13-8:15 a.m.
Discussion Q&A
8:15-8:22 a.m.
22. PIK3CA Mutations are More Frequent in Early-Onset Appendiceal Cancer and Associated with Poorer Survival
Princy Gupta, MBBS
8:22-8:24 a.m.
Discussion Q&A
8:24-8:31 a.m.
23. Neutrophil-related and Other Innate Immune Pathways Are Central to the Tissue Immune Microenvironment in Peritoneal Carcinomatosis
Christopher Sherry, DO
8:31-8:33 a.m.
Discussion Q&A
8:33-8:40 a.m.
24. Neutrophil Infiltration in the Peritoneal Tissue Microenvironment in Carcinomatosis
Christopher Sherry, DO
8:40-8:42 a.m.
Discussion Q&A
8:42-8:49 a.m.
25. Apoptotic Markers in HIPEC Effluent as Predictors of Peritoneal Recurrence: A Novel Biomarker Approach
Eran Nizri
8:49-8:51 a.m.
Discussion Q&A
8:51-8:58 a.m.
26. Tumor-Associated Macrophage Subsets in Appendiceal Cancer
Christopher Sherry, DO
8:58-9:00 a.m.
Discussion Q&A
|
Orangedale Ballroom |
| 9:00 AM - 10:00 AM |
Symposium: Cytoreduction for Gastric, Small Bowel, and Pancreas
This session will review the role of cytoreduction and HIPEC in patients with gastric cancer, small bowel, and pancreatic cancer peritoneal malignancies. Speakers will review case presentations and their experience in these disease sites. There will be opportunity for audience participation via live poll regarding management in specific case scenarios as well as questions to facilitate engagement.
Upon completion of this session, participants should gain strategies to:
- Understand the role of cytoreduction and HIPEC in patients with gastric cancer and peritoneal metastases
- Understand the role of cytoreduction and HIPEC in patients with small bowel adenocarcinoma and peritoneal metastases
- Identify patient selection criteria for cytoreduction and HIPEC in pancreatic cancer
| 9:00 - 9:20 a.m. |
Gastric Cancer Case Presentations
Deepa R. Magge, MD
|
| 9:20 - 9:40 a.m. |
Small Bowel Case Presentations
Oliver Eng, MD
|
| 9:40 - 10:00 a.m. |
Pancreas Case Presentations
Cornelius A. Thiels, DO, MBA, FACS
|
|
Orangedale Ballroom |
| 10:00 AM - 10:30 AM |
Networking Refreshment Break
|
Heritage 1/2/Hall |
| 10:30 AM - 12:00 PM |
Abstract Presentations: Clinical Trials
10:30-10:37 a.m.
27. Intra-tumoral mucolytic therapy for patients with unresectable pseudomyxoma peritonei: Results of an expanded access program
Michael Wach
10:37-10:39 a.m.
Discussion Q&A
10:39-10:46 a.m.
28. Surgical Intervention for Malignant Bowel Obstruction May Offer Improved Survival: Secondary Analysis of SWOG S1316
Jaewon Lee
10:46-10:48 a.m.
Discussion Q&A
10:48-10:55 a.m.
29. Prospective study of adjuvant oxaliplatin-based PIPAC with concurrent intravenous 5-fluorouracil and folinic acid after curative surgery for pT4a/b colon cancer (Clinicaltrials.gov NCT06091683)
Dario Baratti
10:55-10:57 a.m.
Discussion Q&A
10:57-11:04 a.m.
30. Impact of Peritoneal Carcinomatosis and Malignant Ascites on the Outcome of Malignant Bowel Obstruction: Secondary Analysis of SWOG S1316
Kristen E. Dougherty, MD
11:04-11:06 a.m.
Discussion Q&A
11:06-11:13 a.m.
31. Safety, Feasibility and Immunomodulatory Activity of Intra-peritoneal, Intra-tumoral Lipopolysaccharide in Patients with Peritoneal Carcinomatosis: Results of the Regional Immuno-Oncology Trial (RIOT)-1
Christopher Sherry, DO
11:13-11:15 a.m.
Discussion Q&A
11:15-11:22 a.m.
32. Deep Machine Learning Model for Accurate Quantification of Treatment Response in Peritoneal Carcinomatosis
Shaina Sedighim
11:22-11:24 a.m.
Discussion Q&A
11:24-11:31 a.m.
33. DNA Damage in Live Injured Tumor Cells Enhances the Effectiveness of Immune Checkpoint Blockade: Is it Time for Combined HIPEC + Immunotherapy Trials?
Michael B. Yaffe, MD, PhD
11:31-11:33 a.m.
Discussion Q&A
11:33-11:40 a.m.
34. Leading Consensus from the Ground Up: Leveraging Trainee Collaboration to Create the 2024 Peritoneal Surface Malignancies Consortium Guidelines
Elizabeth L. Godfrey, MD
11:40-11:42 a.m.
Discussion Q&A
11:42-11:49 a.m.
35. Impact of Systematic Discontinuation of Mitomycin C HIPEC for Colorectal Peritoneal Metastasis on Oncologic Outcomes at an NCI Cancer Center
Muhammad Talha Waheed, MD
11:49-11:51 a.m.
Discussion Q&A
11:51-11:58 a.m.
36. Optimal duration of neoadjuvant chemotherapy prior to CRS±HIPEC for colorectal cancer: An ass
|
Orangedale Ballroom |
| 12:00 PM - 1:00 PM |
Lunch Break
|
Heritage 1/2/Hall |
| 12:00 PM - 1:00 PM |
Industry Spotlight Presentations
12:10 - 12:25 p.m.
Industry Spotlight Session 1 (Non-CME)
Company
12:30 - 12:45 p.m.
Industry Spotlight Session 2 (Non-CME)
Company
|
Heritage 1/2/Hall |
| 1:00 PM - 2:30 PM |
Workshop: Strategic Clinical Trial Design and Implementation for Advanced Cancers (Non-CME)
This workshop is designed for surgeons and researchers seeking to broaden their understanding of clinical trial and execution in the context of advanced cancers. The workshop will equip participants with the knowledge necessary to address the issues that are unique to clinical trials for patients with advanced cancers (GI, Sarcoma, and Melanoma). The focus is on addressing the unique challenges associated with clinical trials in advanced cancers, from the initiation phase through to the execution of correlative studies. Participants will gain insights into the nuances of clinical trial organization, including investigator-initiated studies and cooperative group trials. The workshop will cover funding mechanisms, optimal endpoint selection, and the integration of correlative science to enhance trial outcomes. By the end of the session, attendees will have a foundation of what is necessary in clinical trial planning, enabling them to initiate clinical trials in their practice.
Upon completion of this session, participants should gain strategies to:
- Understand foundational principles of clinical trial designs specific to surgeons who manage advanced cancers.
- Explore the structure and organization of institutional and national surgical clinical trials and their application in cancer research.
- Identify and assess funding sources for clinical trials.
- Develop strategies for selecting appropriate endpoints to ensure meaningful results.
- Integrate correlative science effectively.
| 1:00 - 1:15 p.m. |
Considerations of Clinical Trial Design for Advanced Cancer Therapies
Beth Helmink, MD, PhD; Thinzar Lwin, MS
|
| 1:15 - 1:35 p.m. |
Navigating Cooperative Groups for Trials Utilizing Advancing Cancer Therapies
Shishir K. Maithel, MD, FACS, FSSO
|
| 1:35 - 1:40 p.m. |
Discussion Q&A
Panel |
| 1:40 - 2:00 p.m. |
How to Fund Your Trial?
Maheswari Senthil, MD
|
| 2:00 - 2:05 p.m. |
Discussion Q&A
|
Orangedale Ballroom |
| 2:30 PM - 4:00 PM |
Workshop: How to Build an Advanced Therapies Program (Non-CME)
This will be a workshop focused on the operational aspects of setting up advanced therapies programs for melanoma, including regional perfusion, injectable therapies, and adoptive cellular therapies. The workshop will emphasize elements of program development including elements of a multidisciplinary team, considerations for accreditation, logistics/resources, financial considerations, partnerships with industry, and associated research programs.
Upon completion of this session, participants should gain strategies to:
- Develop a multidisciplinary team for advanced therapies
- Recognize the operational and financial considerations in starting an advanced therapies program
- Organize a research program in association with advanced therapies clinical program
| 2:30 - 2:45 p.m. |
Regional Perfusion
Jonathan Zager, MD
|
| 2:45 - 3:00 p.m. |
Adoptive Cell Therapy
Michael E. Egger, MD, MPH
|
| 3:00 - 3:15 p.m. |
Intralesional Therapy
TBD
|
| 3:15 - 4:00 p.m. |
Discussion Q&A
Panel
|
|
Heritage 3/4/5 |
| 2:30 PM - 4:00 PM |
Abstract Presentations: PSM Gastric & CRC
2:30-2:37 p.m.
37. International Multi-Institutional Validation Study of Novel Deep Machine Learning Artificial Intelligence Model to Predict Risk of Peritoneal Carcinomatosis in Gastric Cancer
Arsha Ostowari
2:37-2:39 p.m.
Discussion Q&A
2:39-2:46 p.m.
38. Intraperitoneal Paclitaxel Induces Recruitment of Activated Eosinophils to the Peritoneal Cavity, Potentially Contributing to Anti-Tumor Effects Against Peritoneal Metastasis in Gastric Cancer
Joji Kitayama
2:46-2:48 p.m.
Discussion Q&A
2:48-2:55 p.m.
39. Bidirectional laparoscopic HIPEC for palliative and curative intent in gastric cancer peritoneal metastasis
Kristofor Olson, MD, PhD
2:55-2:57 p.m.
Discussion Q&A
2:57-3:04 p.m.
40. Patient Selection for Cytoreductive Surgery and HIPEC for Gastric Cancer with Peritoneal Metastasis
EeeLN Buckarma, MD
3:04-3:06 p.m.
Discussion Q&A
3:06-3:13 p.m.
41. Inter-rater Reliability of Laparoscopic Peritoneal Carcinomatosis Index Assessment after PIPAC
Muhammad Talha Waheed, MD
3:13-3:15 p.m.
Discussion Q&A
3:15-3:22 p.m.
42. Application of Pressurized IntraPeritoneal Aerosolised Chemotherapy in a tertiary academic center- a first real world US case series
David Resstle, MD
3:22-3:24 p.m.
Discussion Q&A
3:24-3:31 p.m.
43. Consensus Molecular Subtype Specific Drug Sensitivities in Colorectal Cancer: New Insights for Personalized HIPEC Strategies
Princy Gupta, MBBS
3:31-3:33 p.m.
Discussion Q&A
3:33-3:40 p.m.
44. The impact of hyperthermia and mitomycin C on heat shock and mismatch repair proteins in colon cancer
Hannah McDonald, MD
3:40-3:42 p.m.
Discussion Q&A
3:42-3:49 p.m.
45. Is there value in repeat CRS±HIPEC for colorectal cancer peritoneal metastases?
Kailey M. Oppat, MD
3:49-3:51 p.m.
Discussion Q&A
3:51-3:58 p.m.
46. NF2 and Downstream Genes are Potential Targets for Treatment in Peritoneal Mesothelioma
Rui Zheng-Pywell
3:58-4:00 p.m.
Discussion Q&A
|
Orangedale Ballroom |
| 4:30 PM - 6:00 PM |
Meet the Professors Reception
|
Laguna Lawn & Heritage Patio |
|
Monday, February 17
|
| 7:00 AM - 7:30 AM |
Breakfast
|
Heritage 1/2/Hall |
| 7:00 AM - 11:00 AM |
Exhibits
|
Heritage 1/2/Hall |
| 7:00 AM - 12:00 PM |
Registration
|
The Canal Club Foyer |
| 7:30 AM - 9:00 AM |
Abstract Presentations: Melanoma & Sarcoma
7:30-7:37 a.m.
47. Outcomes of Clinically Detected Stage III Melanoma Through Individualized Neoadjuvant (PRADO) Approach At a Single Institution
Drew Erali, MD, MPH
7:37-7:39 a.m.
Discussion Q&A
7:39-7:46 a.m.
48. Real-World Experience of Neoadjuvant Immunotherapy for Melanoma
Aleigha Lawless
7:46-7:48 a.m.
Discussion Q&A
7:48-7:55 a.m.
49. T-VEC Shifts CD8 Phenotype to Reverse Anti-PD1 Resistance
Aparna Vancheswaran, MD
7:55-7:57 a.m.
Discussion Q&A
7:57-8:04 a.m.
50. Digital Spatial Proteomics Reveals Immune Microenvironment Dynamics in Melanoma Brain Metastases and Correlates with Treatment Response and Survival
David G. Su, MD
8:04-8:06 a.m.
Discussion Q&A
8:06-8:13 a.m.
51. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases
Michelle M. Dugan, MD
8:13-8:15 a.m.
Discussion Q&A
8:15-8:22 a.m.
52. Relationship of Mitochondrial Complex I Activity and Response to Immunotherapy Treatment in Melanoma Patients
Annmarie F. Butare, DO
8:22-8:24 a.m.
Discussion Q&A
8:24-8:31 a.m.
53. Isolated limb infusion/perfusion for unresectable acral versus non-acral melanoma in-transit metastases
Jacob Israeli, BS
8:31-8:33 a.m.
Discussion Q&A
8:33-8:40 a.m.
54. Impact of sentinel lymph node biopsy on recurrence and survival for Merkel cell carcinoma
Nicholas Chin, BS
8:40-8:42 a.m.
Discussion Q&A
8:42-8:49 a.m.
55. Quadruple negative gastrointestinal stromal tumor demonstrates heterogenous dysregulation of RAS-MAPK signaling and DNA repair
Andrew M. Fleming, MD
8:49-8:51 a.m.
Discussion Q&A
8:51-8:58 a.m.
56. Outcomes of In-Transit Melanoma (ITM) Treated with Checkpoint Inhibitors (CPI) In The Modern Era
Shanie Shemla, MD
8:58-9:00 a.m.
Discussion Q&A
|
Orangedale Ballroom |
| 8:30 AM - 9:30 AM |
Symposium: Management of Regionally Advanced and Metastatic Disease when Systemic Therapy Fails
The treatment of regionally advanced and metastatic melanoma has rapidly progressed over the last decade with the development of immune checkpoint inhibitors and targeted therapy with BRAF/MEK inhibitors. Unfortunately, the majority of patients with regionally advanced or metastatic disease carry intrinsic resistance or will develop acquired resistance to these systemic therapies. Novel strategies to improve responses include upfront immunotherapy for resectable disease (neoadjuvant), adoptive T-cell therapies (clonal T-cell effectors) and oncolytic viral vectors to stimulate immunogenicity or direct targeting of tumor cells. Each of these approaches may be synergistic with the others and may provide windows for surgical intervention in these high-risk settings.
Upon completion of this session, participants should gain strategies to:
- Understand the role and current clinical data on neoadjuvant immunotherapy in regionally advanced melanoma.
- Understand the state of the science of adoptive T-cell therapy and current data that led to recent US FDA approval of TIL for melanoma.
- Describe the role of oncolytic viruses in melanoma and the latest developments in this intralesional strategy.
| 8:30 - 8:32 a.m. |
Introduction
Sonia Cohen, MD, PhD; Richard Essner, MD
|
| 8:32 - 8:47 a.m. |
Neoadjuvant: Update on Trials, Including Nadina
Charlotte Ariyan, MD, PhD
|
| 8:47 - 9:02 a.m. |
TIL: Standard of Care vs Trial Experience
Amanda Kirane, MD, FACS, FSSO
|
| 9:02 - 9:17 a.m. |
Updates on TVEC/Oncolytic Viruses
Edmund Bartlett, MD
|
| 9:17 - 9:30 a.m. |
Discussion Q&A
Panel |
|
Orangedale Ballroom |
| 9:30 AM - 10:00 AM |
Networking Refreshment Break
|
Heritage 1/2/Hall |
| 10:30 AM - 11:35 AM |
Abstract Presentations: PSM Potpourri
10:32-10:39 a.m.
57. P53 and/or SMAD4 mutations are associated with poorest survival in high-grade appendiceal peritoneal metastasis and may be a potential preoperative marker for CRS/HIPEC selection
Chunmeng Zhang
10:39-10:41 a.m.
Discussion Q&A
10:41-10:48 a.m.
58. Efficacy and toxicity of Bevacizumab in the treatment of metastatic Appendiceal Adenocarcinoma
Jean P. Shen
10:48-10:50 a.m.
Discussion Q&A
10:50-10:57 a.m.
59. Histology of Recurrent Mucinous Appendiceal Cancer after CRS-HIPEC for Low Grade Peritoneal Metastases
Sohini Khan
10:57-10:59 a.m.
Discussion Q&A
10:59-11:06 a.m.
60. Appendiceal cancers display immunosuppressed microenvironment and mucin infiltration on multiplex immunofluorescence analysis
Carlos I. Ayala-Navarro, MD, PhD
11:06-11:08 a.m.
Discussion Q&A
11:08-11:15 a.m.
61. Clinical outcomes of high-grade appendiceal mucinous neoplasms
Ashlee N. Seldomridge, MD
11:15-11:17 a.m.
Discussion Q&A
11:17-11:24 a.m.
62. Ac-225 delivered by self-assembling dis-assembling (SADA) bispecific antibodies ablates colorectal and appendiceal peritoneal xenografts with minimal toxicity
Nicole Aguirre, MD
11:24-11:26 a.m.
Discussion Q&A
11:26-11:32 a.m.
63. True Incidence of Appendiceal Neoplasms in Patients Presenting with Complicated Appendicitis: A Call for a Revised Management Algorithm
Laleh Foroutani
11:32-11:34 a.m.
Discussion Q&A
|
Orangedale Ballroom |
| 11:00 AM - 12:30 PM |
Exhibitor Move-Out
|
Heritage 1/2/Hall |
| |
